Varicella vaccine

ApprovedVaccine

Sanofi

Varicella vaccine is one of 70 biologic programs targeting Japanese encephalitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

HepatitisActive, not recruiting

InfluenzaActive, not recruiting

Japanese EncephalitisPhase 3

Active, not recruiting

HepatitisApproved

Active, not recruiting

InfluenzaApproved

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Varicella vaccine

Sanofi

Approved

1 2

Fluzone

GSK

Preclinical

37 3

Crestor

AstraZeneca

Preclinical

1 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Immunogenicity

NCT07473427

Q4 2028

Not yet recruiting

Varicella

NCT06482216

Clinical

Trials by Indication[1]

Immunogenicity4 trials

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Completed· Sanofi logo

Sanofi·Phase 3·NCT03537508·2,627 enrolled

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

Completed·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 3·NCT06314724·642 enrolled

The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination

Unknown status·BBeijing Center for Disease Control and Prevention·Phase 4·NCT01830283·50,000 enrolled

Show 1 more trial

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial

Not yet recruiting·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 3·NCT07473427·300 enrolled

Varicella3 trials

Correlation of Protection Against Varicella in an Exploratory Study

Not yet recruiting·SSinovac (Dalian) Vaccine Technology Co., Ltd.··NCT06482216·400 enrolled

Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.

Withdrawn·UUniversity of Colorado, Denver··NCT02692066

Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine

Withdrawn·UUniversity of Colorado, Denver·Phase 4·NCT02026089

Hepatitis2 trials

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine

Unknown status·UUniversity of Witwatersrand, South Africa·Phase 4·NCT03330171·278 enrolled

Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 2/3·NCT00926419·600 enrolled

MMR Vaccine1 trial

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine

Not yet recruiting·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 4·NCT06891872·720 enrolled

Vaccination1 trial

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Completed· Novartis logo

Novartis·Phase 3·NCT00806195·7,744 enrolled

6 more indications

Children1 trial

A Study of MG1111 in Healthy Children

Completed·GGreen Cross Corporation·Phase 2/3·NCT03375502·814 enrolled

Immunization1 trial

Study on Booster Immunization With Varicella Vaccine at Different Intervals

Completed·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 4·NCT06994052·412 enrolled

Japanese encephalitis1 trial

Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV

Completed· Sanofi logo

Sanofi·Phase 3·NCT01190228·454 enrolled

Solid Organ Transplant1 trial

The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation

Completed·TThe Hospital for Sick Children·Phase 3·NCT00213304·21 enrolled

Influenza1 trial

Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)

Completed·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 4·NCT06987942·899 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation

Completed·UUniversity of California, San Francisco··NCT01581164·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Varicella vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Varicella vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Varicella vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Sanofi

Varicella vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Immunogenicity4 trials

Varicella3 trials

Hepatitis2 trials

MMR Vaccine1 trial

Vaccination1 trial

Children1 trial

Immunization1 trial

Japanese encephalitis1 trial

Solid Organ Transplant1 trial

Influenza1 trial

Hematopoietic Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News